In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Supernus Pharmaceuticals' current price is 66.8% below a high-confidence fair value of $69.25, indicating potential undervaluation amid strong DCF valuation. However, weak profitability and high leverage raise financial risks. Monte Carlo analysis shows high volatility but limited downside risk below current price, suggesting asymmetric opportunity.